Your session is about to expire
← Back to Search
Part A: EDG-7500 Single Dose for Hypertrophic Cardiomyopathy
Study Summary
This trial aims to investigate the safety and impact of different amounts of EDG-7500 in adults with a heart condition called obstructive hypertrophic cardiomyopathy, by giving either one dose or multiple
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current number of individuals being enrolled in this research investigation?
"Indeed, data on clinicaltrials.gov indicates that this trial is actively enrolling participants. The trial was initially posted on the 4th of January 2024 and most recently updated on the 2nd of April 2024. This study aims to recruit a total of 30 individuals from a single site."
Are there any available openings for patients to participate in this study?
"Indeed, as per clinicaltrials.gov data, this clinical trial is presently seeking individuals for participation. The trial was first made publicly available on April 1st, 2024 and underwent its most recent update on April 2nd, 2024. Enrollment aims to reach a total of 30 participants at one designated site."
What are the risks associated with Part A: EDG-7500 Single Dose for individuals?
"Based on the trial phase, our team at Power assesses the safety of Part A: EDG-7500 Single Dose as a 2. This suggests that while there is existing safety data, efficacy evidence is lacking."
Share this study with friends
Copy Link
Messenger